Indivior Pharmaceuticals, Inc.
INDV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001625297
In the last 90 days, Indivior Pharmaceuticals, Inc. insiders filed 2 open-market purchases and 1 sale; 337 institutions reported holding it in 13F filings for Q2 2026, worth $4.98B in total; Oaktree Capital is the only superinvestor holding it.
Q3 2023 vs. Q2 2023
How the institutions holding Indivior Pharmaceuticals, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 60 | 76 | +16 |
| Shares | 62.0M | 68.1M | +6.14M (+9.9%) |
| Value | $1.46B | $1.53B | +$76.6M (+5.3%) |
New holders (20)
Institutions that held Indivior Pharmaceuticals, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Liontrust Investment Partners LLP | 1,995,889 | $43.3M | 0.69% |
| Credit Agricole S A | 956,169 | $22.1M | 0.68% |
| Janus Henderson Group PLC | 385,371 | $8.37M | 0.01% |
| Exor Capital LLP | 273,565 | $5.94M | 0.32% |
| Polar Asset Management Partners Inc. | 161,900 | $3.52M | 0.08% |
| Deutsche Bank AG | 137,901 | $3.18M | 0.00% |
| Amundi | 138,880 | $2.69M | 0.00% |
| Campbell & CO Investment Adviser LLC | 36,911 | $801.4K | 0.10% |
| Susquehanna International Group, LLP | 25,820 | $582.8K | 0.00% |
| Legal & General Group Plc | 5,008 | $108.7K | 0.00% |
| State of Wyoming | 3,075 | $67.6K | 0.01% |
| Russell Investments Group, Ltd. | 2,552 | $55.4K | 0.00% |
| Qube Research & Technologies Ltd | 1,802 | $40.7K | 0.00% |
| NBC Securities, Inc. | 470 | $10.0K | 0.00% |
| Cary Street Partner Investment Advisory LLC | 200 | $4.61K | 0.00% |
| Guardian Wealth Management, Inc. | 160 | $3.69K | 0.00% |
| BlackRock Inc. | 90 | $2.08K | 0.00% |
| Motco | 89 | $2.05K | 0.00% |
| McClarren Financial Advisors, Inc. | 86 | $1.00K | 0.00% |
| Fortis Group Advisors, LLC | 17 | $392 | 0.00% |
Sold out (4)
Institutions that held Indivior Pharmaceuticals, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Soleus Capital Management, L.P. | 18,624 | $443.3K |
| FIL Ltd | 18,444 | $427.0K |
| Ossiam | 12,426 | $288.0K |
| The PNC Financial Services Group, Inc. | 25 | $595 |